Drug intelligence / Profile preview

methyl n-[(2',4'-difluoro-4-hydroxy-5-iodobiphenyl-3-yl)carbonyl]-beta-alaninate

Development stage
Preclinical
Modality
Small Molecules
01

Overview

Methyl N-\[(2',4'-difluoro–4–hydroxy–5–iodobiphenyl–3–yl)carbonyl\]-beta-alaninate is a synthetic small molecule compound with the molecular formula C₁₇H₁₄F₂INO₄ and a molecular weight of approximately 461.20 g/mol. It is also known by the code name IFA. The compound has been studied as an experimental agent and is structurally related to iododiflunisal derivatives. Crystallographic studies have shown that it binds to transthyretin (TTR), a plasma protein involved in thyroid hormone transport and implicated in amyloid diseases such as familial amyloid polyneuropathy. By binding to TTR, this molecule acts as an inhibitor of TTR amyloid fibril formation, potentially stabilizing the native tetrameric form of TTR and preventing pathological aggregation[1][7]. Its primary mechanism appears to be through direct interaction with transthyretin at its thyroxine-binding sites.

Other names
methyl 3-{[5-(2,4-difluorophenyl)-2-hydroxy-3-iodophenyl]formamido}propanoatemethyl n-[(2′,4′-difluoro-4-hydroxy-5-iodo-biphenyl)-3-carbonyl]-β-alaninateβ-alanine, n-[2′,4′‑difluoro‑4‑hydroxy‑5‑iodo[1,1′‑biphenyl]‑3‑yl)carbonyl]-, methyl ester
02

Targets

TTR (Transthyretin)

Beyond the preview

Go deeper on methyl n-[(2',4'-difluoro-4-hydroxy-5-iodobiphenyl-3-yl)carbonyl]-beta-alaninate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methyl n-[(2',4'-difluoro-4-hydroxy-5-iodobiphenyl-3-yl)carbonyl]-beta-alaninate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call